Starrygene

Starrygene is a clinical-stage biotechnology company headquartered in Shanghai, China, specializing in the development of next-generation off-the-shelf immune cell therapies. Founded in 2021 by Dr. Wei (William) Cao, the former CEO of Gracell Biotechnologies, the company focuses on leveraging induced pluripotent stem cell (iPSC) technology to create standardized Chimeric Antigen Receptor Natural Killer (CAR-NK) cells. Their proprietary platform aims to overcome the limitations of autologous CAR-T therapies, such as high manufacturing costs and complex logistics, by providing scalable and readily available treatments. Starrygene's pipeline is primarily directed toward treating solid tumors and hematological malignancies that are underserved by current therapies. The company has established a state-of-the-art GMP manufacturing facility to support its clinical programs and future commercialization efforts.